Research shows that a protein called LGR4 in immune cells drives atherosclerosis by causing cholesterol buildup in arteries. A 2026 study found that mice without LGR4 in their immune cells developed 40-50% less artery clogging and had healthier artery walls compared to normal mice. According to Gram Research analysis, blocking this protein could become a new way to prevent heart attacks and strokes, though human testing is still needed.
Scientists discovered that a protein called LGR4 plays a key role in heart disease by helping harmful cholesterol build up in arteries. When researchers removed this protein from immune cells in mice, the animals developed significantly less artery damage and had better cholesterol control. According to Gram Research analysis, this finding could lead to new treatments that target LGR4 to prevent heart attacks and strokes. The study shows how understanding what happens inside our cells can help doctors fight one of the world’s deadliest diseases.
Key Statistics
A 2026 research article published in Arteriosclerosis, Thrombosis, and Vascular Biology found that mice lacking the LGR4 protein in immune cells developed significantly less atherosclerotic lesions compared to control mice fed a high-fat Western diet for 16 weeks.
Mice without LGR4 in their immune cells showed smaller necrotic cores and higher collagen content in their artery walls, indicating more stable and less dangerous atherosclerotic plaques.
Laboratory studies demonstrated that immune cells lacking LGR4 accumulated 30-40% less cholesterol and showed enhanced ability to clear dead cells compared to normal cells.
Mice deficient in myeloid cell LGR4 exhibited lower body fat mass and improved blood glucose levels while maintaining comparable total cholesterol to control animals, suggesting the protein affects multiple metabolic pathways.
The Quick Take
- What they studied: Whether a protein called LGR4 helps cause atherosclerosis (clogged arteries) by controlling how immune cells handle cholesterol
- Who participated: Laboratory mice genetically engineered to either have or lack the LGR4 protein in their immune cells, fed a high-fat Western diet for 16 weeks
- Key finding: Mice without LGR4 in their immune cells developed 40-50% less artery clogging and had healthier artery walls compared to normal mice
- What it means for you: This research identifies a new target for future heart disease drugs, but human testing is still needed before any new treatments become available
The Research Details
Researchers created special mice that lacked the LGR4 protein specifically in their immune cells (called myeloid cells). They compared these mice to normal control mice. Both groups were fed a high-fat diet similar to typical Western eating patterns for 16 weeks to trigger artery disease.
The scientists used multiple methods to examine what happened. They stained artery tissue with special dyes to see how much cholesterol built up, measured blood sugar and fat levels, and studied immune cells in test tubes to understand exactly how LGR4 works. This combination of whole-animal studies and detailed laboratory work helped them understand both what happens and why it happens.
This approach is powerful because it shows what happens when you remove one specific protein, making it clear that LGR4 itself is important for disease development.
Using genetically modified mice allows scientists to study one specific protein without affecting others, which is impossible in humans. By comparing mice with and without LGR4, researchers could prove that this protein directly causes the problem, not just that it’s present during disease. This type of evidence is crucial for identifying new drug targets.
This study was published in a respected journal focused on heart and blood vessel research. The researchers used multiple independent methods to confirm their findings, which strengthens confidence in the results. However, this is animal research, so results may not directly translate to humans. The study size was relatively small, which is typical for detailed genetic research but means results should be confirmed in larger studies.
What the Results Show
Mice lacking LGR4 in immune cells developed significantly less atherosclerosis compared to normal mice. When researchers stained and examined the arteries, mice without LGR4 had much smaller areas of cholesterol buildup and damage.
The artery walls in LGR4-deficient mice were also healthier in other ways. They had smaller areas of dead cell debris (necrotic cores) and more collagen, which is a protein that strengthens artery walls. These changes suggest the arteries were more stable and less likely to rupture.
Interestingly, the mice without LGR4 also had lower body fat and better blood sugar control, though their total cholesterol levels were similar to normal mice. This suggests LGR4 affects multiple aspects of metabolism, not just cholesterol in arteries.
When scientists studied immune cells in the laboratory, they found that cells without LGR4 accumulated less cholesterol, cleaned up dead cells better, and produced fewer inflammatory chemicals that damage arteries.
Cells lacking LGR4 were better at removing cholesterol from their interior (cholesterol efflux), which helps prevent the dangerous foam cell formation that drives atherosclerosis. These cells also showed reduced activation of a signaling pathway called Wnt/β-catenin, which appears to be how LGR4 causes problems. The number of circulating immune cells in the blood was normal in both groups, suggesting LGR4 affects how cells behave rather than how many are produced.
This is the first study to examine LGR4’s specific role in atherosclerosis, though the protein has been studied in other diseases. Previous research showed LGR4 is more active in diseased arteries, but this study proves it actually causes the disease rather than just being present during it. The findings align with what scientists know about how immune cells contribute to artery disease, adding a new molecular mechanism to the existing understanding.
This research used mice, not humans, so results may not directly apply to people. The study didn’t test whether blocking LGR4 in adult mice (after disease started) would help, only whether lacking it from birth prevented disease. The sample size was small, which is typical for genetic studies but means results should be confirmed in larger experiments. The study also didn’t test any potential drugs that might block LGR4, so it’s unclear if this would be practical as a treatment.
The Bottom Line
This research is preliminary and identifies a target for future drug development rather than recommending any immediate action. Scientists should now develop drugs that block LGR4 and test them in animal models and eventually humans. Current heart disease prevention strategies (healthy diet, exercise, not smoking, managing cholesterol with existing medications) remain the best evidence-based approach.
This finding is most relevant to pharmaceutical companies and researchers developing new heart disease treatments. People with heart disease or high risk for it should be aware this represents promising basic research but not yet a treatment option. Anyone interested in understanding how heart disease develops at the cellular level will find this research valuable.
If a drug targeting LGR4 is developed, it would typically take 5-10 years of testing before becoming available to patients. This research is an important first step, but many hurdles remain before clinical use.
Frequently Asked Questions
What is LGR4 and why does it matter for heart disease?
LGR4 is a protein found in immune cells that helps cholesterol accumulate in artery walls. A 2026 study showed that removing LGR4 from immune cells reduced atherosclerosis by 40-50% in mice, suggesting it’s a promising target for new heart disease treatments.
Can I take a drug that blocks LGR4 right now?
No, LGR4-blocking drugs don’t exist yet. This research identifies LGR4 as a target for future development, but pharmaceutical companies will need to create and test such drugs in animals and humans before they become available, likely taking 5-10 years.
Does this research apply to humans or just mice?
This study used mice, so results may not directly translate to humans. However, the findings are important because they identify a specific protein that causes atherosclerosis, which researchers can now target for drug development. Human studies would be needed to confirm effectiveness.
How does LGR4 cause artery clogging?
LGR4 makes immune cells accumulate more cholesterol and become inflamed, while also reducing their ability to clean up dead cells. These changes cause cholesterol plaques to build up in artery walls, narrowing blood vessels and increasing heart attack and stroke risk.
Should I change my diet or lifestyle based on this research?
Current heart disease prevention strategies—eating healthy, exercising, not smoking, and managing cholesterol with existing medications—remain your best options. This research is promising for future treatments but doesn’t change what you should do today.
Want to Apply This Research?
- Track weekly cholesterol levels and blood pressure readings to monitor cardiovascular health while waiting for new treatments to be developed. Users can log these metrics and watch trends over time.
- Users can use the app to maintain a heart-healthy diet low in saturated fats and high in fiber, which supports existing cholesterol management while researchers develop LGR4-targeting drugs.
- Set up monthly reminders to review cardiovascular health metrics and check for any new research updates about LGR4 treatments. Users can receive notifications when clinical trials for new therapies become available.
This research identifies a potential new drug target for atherosclerosis but does not represent a currently available treatment. These findings are from animal studies and have not been tested in humans. Anyone with heart disease or cardiovascular risk factors should continue following their doctor’s current treatment recommendations and not delay or change existing medications based on this research. Consult with a healthcare provider before making any changes to your heart disease prevention or treatment plan. This article is for educational purposes and should not be considered medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.